Analyst Price Target is $14.80
▲ +108.74% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Evolus in the last 3 months. The average price target is $14.80, with a high forecast of $20.00 and a low forecast of $10.00. The average price target represents a 108.74% upside from the last price of $7.09.
Current Consensus is
The current consensus among 5 polled investment analysts is to buy stock in Evolus. This Buy consensus rating has held steady for over two years.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.